Retatrutide side effects: what the trials counted

Reviewed 16 sourcesPublished by PepVault

Retatrutide side effects by dose in its trials: nausea, diarrhoea, skin tingling and heart rate, when they show up, how many stopped, and what helps.

A man in a white t-shirt holding a cup of ginger tea in both hands, yogurt with berries, ginger and lemon on a board in front of him
Last reviewed
Sources
16
Questions
9
Compounds
3

The short answer

In retatrutide's trials the common side effects were stomach ones: nausea, diarrhoea, constipation and vomiting. They were mostly mild to moderate, rose with the dose and came mainly in the step-up weeks. Some people also felt tingling or extra-sensitive skin, or saw a faster resting pulse. Smaller meals, eating slowly, steady fluids and fibre help, and most participants stayed on treatment.

Every number checked at its primary source · · 16 sources · How we research

Evidence: Randomised phase 2 and phase 3 trials in people, published in NEJM, The Lancet and Nature Medicine; several phase 3 side-effect tables come from Lilly's company releases, not peer-reviewed papers, plus one study of social-media self-reports.

A man in a white t-shirt holding a cup of ginger tea in both hands, yogurt with berries, ginger and lemon on a board in front of him

What are the most common side effects of retatrutide?

Stomach effects, by a wide margin. Retatrutide works three hormone receptors: GIP, GLP-1 and glucagon1. GLP-1 slows how fast the stomach empties, so food sits longer, and that slowing goes with much of the nausea and fullness. In the phase 2 obesity trial these events were dose-related and mostly mild to moderate1.

Retatrutide is investigational: it is not approved by the FDA14. So there is no label yet, and every figure here comes from a trial. TRIUMPH-1, the large phase 3 trial in 2,339 adults with obesity and no diabetes, ran for 80 weeks7. Its side-effect rates come from Lilly's press releases, which are company statements, not peer-reviewed papers. This is the share of people in each group who reported each effect813:

Effect4 mg9 mg12 mgPlacebo
Nausea28.6%38.4%42.4%14.8%
Diarrhoea25.2%34.1%32.0%13.5%
Constipation23.8%25.9%26.1%10.9%
Vomiting10.6%22.8%25.3%4.8%
Dysesthesia (skin sensations)5.1%12.3%12.5%0.9%
Urinary tract infection7.5%8.8%8.4%5.3%
Stopped because of side effects4.1%6.9%11.3%4.9%
Bar chart: in TRIUMPH-1, nausea, diarrhoea, constipation, vomiting and skin sensations rose with the retatrutide dose, each above placebo
Share of people in TRIUMPH-1 who reported each effect over 80 weeks, by dose. Placebo is the grey bar; the gap above it is what the drug adds. Figures from Lilly's press release of May 21, 2026.

Placebo groups report nausea and diarrhoea too, from ordinary life over 80 weeks. The gap between a dose and placebo is the part the drug adds.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's dose log keeps each shot with its date, and its reminders keep the weekly day steady.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Are the side effects the same in every trial?

The pattern holds across the programme, and the size moves with who was enrolled. Here is the top dose, 12 mg, in six trials, each against its comparison group. In TRANSCEND-T2D-2 that comparison was Ozempic 2 mg, semaglutide's highest approved diabetes dose, instead of placebo14.

Trial, 12 mg armNauseaDiarrhoeaVomitingDysesthesiaStopped for side effects
TRIUMPH-1: obesity, 80 weeks42.4% vs 14.8%32.0% vs 13.5%25.3% vs 4.8%12.5% vs 0.9%11.3% vs 4.9%
TRIUMPH-4: obesity and knee osteoarthritis, 68 weeks43.2% vs 10.7%33.1% vs 13.4%20.9% vs 0.0%20.9% vs 0.7%18.2% vs 4.0%
TRIUMPH-2: obesity and type 2 diabetes, 80 weeks28.0% vs 8.0%33.6% vs 13.2%15.7% vs 4.2%7.3% vs 0.7%7.7% vs 4.9%
TRIUMPH-3: obesity and cardiovascular disease, 80 weeks22.4% vs 5.8%24.4% vs 8.7%Not listed6.4% vs 1.3%13.5% vs 4.8%
TRANSCEND-T2D-1: type 2 diabetes, 40 weeks26.5% vs 3.7%22.8% vs 4.5%17.6% vs 2.2%4.4% vs 0.0%5.1% vs 0.0%
TRANSCEND-T2D-2: type 2 diabetes, vs Ozempic 2 mg, 80 weeks23.8% vs 21.3%32.7% vs 26.4%15.0% vs 13.2%6.5% vs 2.7%7.9% vs 2.7%

The rows come from Lilly's company releases89111314; the published TRIUMPH-2 paper gives the same picture in whole numbers10. Two things stand out. Against Ozempic 2 mg, the stomach effects of retatrutide 12 mg ran close to semaglutide's14. And TRIUMPH-4 had the highest skin-sensation and stopping rates, which the section on stopping below explains9.

When do retatrutide side effects show up?

Mostly in the climb. In phase 2, the stomach effects usually came during the dose-escalation period5, the weeks when the dose is being stepped up, and in its liver substudy they were transient and came primarily during escalation6. In TRANSCEND-T2D-1 they subsided over time12. The phase 3 trials start at 2 mg and step up every four weeks, so in the 12 mg arm the climbing weeks are the first 168.

The starting dose matters. Both phase 2 trials ran the same target dose from a 2 mg start and from a 4 mg start. In the obesity trial the lower start partly eased the stomach effects1, and the posted results of both trials show it most clearly for nausea, in groups of 23 to 35 people each24:

Trial and target doseNausea, 2 mg startNausea, 4 mg startVomiting, 2 mg startVomiting, 4 mg start
Obesity trial, 4 mg18% (6 of 33)36% (12 of 33)12% (4 of 33)12% (4 of 33)
Obesity trial, 8 mg17% (6 of 35)60% (21 of 35)6% (2 of 35)26% (9 of 35)
Type 2 diabetes trial, 4 mg9% (2 of 23)25% (6 of 24)4% (1 of 23)0% (0 of 24)
Type 2 diabetes trial, 8 mg27% (7 of 26)42% (10 of 24)8% (2 of 26)17% (4 of 24)

On placebo, nausea was 11% in the obesity trial and 4% in the diabetes trial24. In the diabetes trial the 4 mg arm with a 4 mg start had no climb at all; it began at its full dose3.

What helps with nausea and constipation on retatrutide?

Ordinary habits do most of the work, and they matter most in the week after a step-up.

  1. Serve yourself a smaller plate than you used to.
  2. Stop eating at the first sign of fullness, even with food left on the plate.
  3. Eat slowly, putting your fork down between bites.
  4. In the days after a step-up, keep fried, fatty and very rich food off your plate.
  5. Sip water through the day, and sip more on any day you have diarrhoea or vomiting.
  6. When constipation shows up, add fibre a little at a time, with extra water.
  7. Stay upright for a while after you eat if you get reflux or burping.
  8. Stand up slowly if you feel light-headed.

The trials had a fallback too: when stomach effects or eating stayed hard despite these habits, a person could step back down and climb again, and after that move to a lower dose for good15. PepVault's guide to retatrutide dosage in trials covers those schedules.

Commonly reported: queasiness strongest in the first days after a step-up, burping and heavy fullness after rich meals, tiredness, poorer sleep, and skin that tingles on and off.

When to get help Call a doctor the same day if you cannot keep fluids down, have belly pain that is severe and does not ease, or feel your pulse racing with chest discomfort or fainting.

How do I keep track of side effects after each step-up?

A short record turns a vague week into something you can show a clinician: which dose, which day, what you felt and how strong.

  • Write down the date of every dose change, so a new symptom can be matched to the step before it.
  • Rate each symptom the same way every time, from minimal to very severe, and note what you ate that day.

PepVault's dose log keeps each shot with its date, and its reminders keep the weekly day steady. Log it in PepVault

PepVault's side-effect log records each symptom with the compound, a severity from minimal to very severe, the date and a note. Log it in PepVault

What is dysesthesia, and how common was it?

Dysesthesia is an unusual skin sensation: tingling, burning, or skin that feels more sensitive to touch than it should. It is the side effect that sets retatrutide's trials apart. In TRIUMPH-1 it rose from 5.1% on 4 mg to 12.5% on 12 mg, against 0.9% on placebo; the events were generally mild to moderate, the majority resolved during treatment, and most participants kept taking retatrutide8.

The highest rate so far is TRIUMPH-4: 8.8% on 9 mg and 20.9% on 12 mg, against 0.7% on placebo, generally mild, and it rarely led anyone to stop9. Phase 2 had already shown a small signal. In its 12 mg group of 62, four people reported allodynia, pain from a touch that should not hurt, and two reported hyperaesthesia, extra skin sensitivity, against none and one of 70 on placebo2.

Does retatrutide raise your heart rate?

Yes, and the rise eases. In the phase 2 obesity trial, heart rate rose with the dose, peaked at week 24 and declined after that1. The sources here do not give its size in beats per minute.

Blood pressure can go the other way. In TRIUMPH-2, low blood pressure was reported by 1% on 4 mg, 5% on 9 mg and 6% on 12 mg, against under 1% on placebo10. Steady fluids and standing up slowly help with the light-headed moments.

How many people stopped retatrutide because of side effects?

A minority, and fewer at lower doses. In TRIUMPH-1, 4.1% on 4 mg stopped because of side effects, slightly fewer than the 4.9% on placebo, against 11.3% on 12 mg8. In TRIUMPH-2 it was 3.8%, 11.6% and 7.7% on 4, 9 and 12 mg, against 4.9% on placebo11.

TRIUMPH-4 shows what sits inside those numbers. There, 12.2% on 9 mg and 18.2% on 12 mg stopped for side effects, against 4.0% on placebo. Lilly reports that the rates were highly correlated with starting BMI and included people who stopped for what they felt was too much weight loss. Among people who started at a BMI of 35 or more, 84% of the trial, the rates were 8.8% and 12.1%, against 4.8%, so people who started lighter stopped more often9. Serious adverse events were no more common than on placebo in the phase 2 obesity trial: 10 of 267 people on retatrutide (3.7%) and 3 of 70 on placebo (4.3%)2.

What do people report outside the trials?

A 2026 study read social-media posts from people who said they were taking retatrutide outside a trial. Among 7,823 users who described at least one symptom, the most mentioned included increased appetite (17.1%), tiredness (15.2%), nausea (11.6%), trouble sleeping (6.1%) and a faster heart rate (4.8%)16. The authors call the findings hypothesis-generating: the product, its dose and the person's health could not be checked, so the study cannot give rates or causes the way a trial does16.

Track it in the app

Sources

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
  2. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Results record: adverse events. clinicaltrials.gov
  3. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PubMed 37385280
  4. ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Results record: adverse events. clinicaltrials.gov
  5. Eli Lilly and Company. Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. Press release, June 26, 2023. prnewswire.com
  6. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PubMed 38858523
  7. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
  8. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026. prnewswire.com
  9. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). Press release, Dec 11, 2025. prnewswire.com
  10. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
  11. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3). Press release, July 23, 2026. prnewswire.com
  12. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a phase 3 trial. Lancet. 2026. PubMed 42250575
  13. Eli Lilly and Company. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea (TRIUMPH-1 and TRANSCEND-T2D-1 at ADA). Press release, June 6, 2026. prnewswire.com
  14. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, Oct 28, 2026. prnewswire.com
  15. Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. PubMed 41090431
  16. Sehgal NKR et al. Self-reported adverse effects among social media users taking nonapproved retatrutide. JAMA Netw Open. 2026. PubMed 42873503

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo